Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 30, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)

Company name: EIKEN CHEMICAL CO.,LTD.
Listing: Tokyo Stock Exchange
Securities code: 4549
URL: https://www.eiken.co.jp
Representative: Yuji Segawa President & CEO
Inquiries: Tomohiro Kudo Executive Officer
Telephone: +81-3-5846-3379
Scheduled date to commence dividend payments: -
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	10,728	5.2	667	(16.7)	640	(21.3)	445	(25.8)
June 30, 2025	10,197	7.1	800	37.2	813	26.8	600	23.4

(Note) Comprehensive income Three months ended June 30, 2026: ¥ 419 million [(30.7) %]
Three months ended June 30, 2025: ¥ 605 million [10.6%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	13.52	13.49
June 30, 2025	18.21	18.04

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
June 30, 2026	61,895	43,497	70.1	1,316.79
March 31, 2026	62,657	44,034	70.1	1,333.07

(Reference) Equity
As of June 30, 2026: ¥ 43,408 million
As of March 31, 2026: ¥ 43,945 million

2. Cash dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	29.00	-	29.00	58.00
Fiscal year ending March 31,2027	-				
Fiscal year ending March 31, 2027 (Forecast)		29.00	-	29.00	58.00

(Note) Revisions to the forecast of cash dividends most recently announced: None

(Note) Breakdown of the first quarter dividend for the fiscal year ending March 31, 2027 :

Commemorative dividend - yen

Special dividend - yen

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2026	21,100	3.3	1,720	(0.5)	1,640	(5.2)	1,170	(60.7)	35.49
Full year	42,000	0.2	3,070	5.2	2,900	2.0	2,070	(44.2)	62.79

(Note) Revisions to the financial result forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - (Company name:)

Excluded: - (Company name:)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

1)Changes in accounting policies due to revisions to accounting standards and other regulations: None

2)Changes in accounting policies due to other reasons: None

3)Changes in accounting estimates: None

4)Restatement: None

(4) Number of issued shares (common shares)

1)Total number of issued shares at the end of the period (including treasury shares)

June 30, 2026	34,541,438 shares
March 31, 2026	34,541,438 shares

2)Number of treasury shares at the end of the period

June 30, 2026	1,575,865 shares
March 31, 2026	1,575,865 shares

3)Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	32,965,573 shares
Three months ended June 30, 2025	32,985,383 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Table of Contents - Attachments

1. Overview of Consolidated Business Performance

(1) Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year

During the first quarter of the consolidated fiscal year under review, the domestic and overseas economies remained uncertain due to the effects of surging resource prices and geopolitical risks. The business environment became increasingly severe in the clinical diagnostics industry due to measures to cap medical expenses and rising costs such as for logistics and raw material procurement, on account of yen depreciation and high crude oil prices. Corporations were obliged to focus on cost competitiveness and to strategically expand overseas.

In the context of this business environment, the Eiken Group is implementing key measures focused on the three key business fields of "Contribution to cancer prevention and treatment," "Contribution to the eradication and control of infectious diseases," and "Provision of products and services useful for health care," while also advancing fundamental reforms aimed at strengthening the Group's overall earnings base, in accordance with the Management Plan 2030. In addition, as a Group with a mission to protect the health of people worldwide, the Eiken Group is addressing issues not only in "Medical," but also in "Environment," "Society," and "Governance." Through these efforts, we strive to further enhance our corporate value and achieve a sustainable society.

The net sales for the first quarter of the consolidated fiscal year under review remained strong growth due to steady overseas markets and amounted to 10,728 million yen (up 5.2% year-on-year). For net sales by product class and type, sales of microbiological testing reagents were 1,050 million yen (down 2.9% year-on-year), and sales of urinalysis reagents were 1,075 million yen (down 9.5% year-on-year) due to a temporary decrease in overseas sales. For sales of immunological and serological reagents were 6,346 million yen (up 6.6% year-on-year) amid sales of fecal immunochemical test reagents remained strong in overseas markets. Sales of clinical chemistry reagents were 143 million yen (down 4.2% year-on-year), and sales of equipment and culture medium for food and environment related category were 451 million yen (down 4.7% year-on-year). Sales in other categories (medical devices, genetic-related products, etc.) were 1,660 million yen (up 23.2% year-on-year) amid an increase in sales of medical devices. For overseas sales were 3,175 million yen (up 14.9% year-on-year) amid an increase in sales of fecal immunochemical test reagents.

Regarding profit, although net sales remained strong growth, amid changes in the sales mix and rising raw material prices, operating profit was 667 million yen (down 16.7% year-on-year) and ordinary profit was 640 million yen (down 21.3% year-on-year) and profit attributable to owners of parent was 445 million yen (down 25.8% year-on-year).

(2) Summary of Consolidated Financial Position for The First Quarter of The Current Fiscal Year

The financial position at the end of the first quarter of the consolidated fiscal year under review was as follows.

When compared to the end of the previous consolidated fiscal year, total assets decreased by 761 million yen, liabilities decreased by 225 million yen, and net assets decreased by 536 million yen.

Major increases and decreases in the category of assets include a decrease of 1,055 million yen in cash and deposits. In the category of liabilities, income taxes payable decreased by 468 million yen. In the category of net assets, despite the recording of profit attributable to owners of parent, shareholders' equity decreased by 510 million yen due to dividend payments.

As a result of the above, the equity ratio remained 70.1%, unchanged from the end of the previous consolidated fiscal year.

(3) Qualitative Information Regarding Forecasts for Consolidated Business Performance

For the consolidated financial results forecasts for the six months ending September 30, 2026 and the consolidated fiscal year ending March 31, 2027, there has been no change in the financial forecast announced on May 12, 2026.

2. Quarterly Consolidated Financial Statements and Primary Notes

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	10,943	9,888
Notes and accounts receivable - trade, and contract assets	10,174	10,353
Electronically recorded monetary claims - operating	1,225	2,120
Merchandise and finished goods	4,354	4,207
Work in process	2,024	2,089
Raw materials and supplies	1,613	1,859
Other	1,710	1,180
Allowance for doubtful accounts	(6)	-
Total current assets	32,040	31,699
Non-current assets		
Property, plant and equipment		
Buildings and structures	32,206	32,232
Accumulated depreciation	(14,721)	(14,982)
Buildings and structures, net	17,484	17,250
Machinery, equipment and vehicles	8,735	8,976
Accumulated depreciation	(6,746)	(6,889)
Machinery, equipment and vehicles, net	1,989	2,087
Tools, furniture and fixtures	6,064	6,338
Accumulated depreciation	(5,103)	(5,193)
Tools, furniture and fixtures, net	960	1,145
Land	1,928	1,928
Leased assets	368	368
Accumulated depreciation	(161)	(180)
Leased assets, net	206	188
Construction in progress	767	226
Total property, plant and equipment	23,338	22,826
Intangible assets	332	316
Investments and other assets		
Long-term time deposits	1,200	1,200
Other	5,769	5,875
Allowance for doubtful accounts	(23)	(23)
Total investments and other assets	6,945	7,052
Total non-current assets	30,616	30,195
Total assets	62,657	61,895

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	4,838	5,231
Electronically recorded obligations - operating	2,622	3,002
Current portion of bonds payable	3,000	3,000
Current portion of long-term borrowings	300	300
Income taxes payable	708	240
Provision for bonuses	693	359
Other	2,473	2,305
Total current liabilities	14,636	14,438
Non-current liabilities		
Long-term borrowings	2,650	2,575
Asset retirement obligations	65	65
Other	1,271	1,318
Total non-current liabilities	3,986	3,958
Total liabilities	18,622	18,397
Net assets		
Shareholders' equity		
Share capital	6,897	6,897
Capital surplus	7,892	7,892
Retained earnings	30,884	30,374
Treasury shares	(2,242)	(2,242)
Total shareholders' equity	43,432	42,921
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	25	15
Foreign currency translation adjustment	7	7
Remeasurements of defined benefit plans	480	463
Total accumulated other comprehensive income	513	486
Share acquisition rights	89	89
Total net assets	44,034	43,497
Total liabilities and net assets	62,657	61,895

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statement of Income (For the three months)

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Net sales	10,197	10,728
Cost of sales	6,094	6,650
Gross profit	4,103	4,077
Selling, general and administrative expenses	3,302	3,410
Operating profit	800	667
Non-operating income		
Interest income	4	3
Dividend income	0	4
Rental income	2	-
Subsidy income	27	-
Foreign exchange gains	2	11
Other	8	10
Total non-operating income	45	29
Non-operating expenses		
Interest expenses	4	19
Share of loss of entities accounted for using equity method	23	23
Other	4	13
Total non-operating expenses	32	55
Ordinary profit	813	640
Extraordinary income		
Gain on sale of non-current assets	0	-
Total extraordinary income	0	-
Extraordinary losses		
Loss on sale and retirement of non-current assets	0	0
Total extraordinary losses	0	0
Profit before income taxes	814	640
Income taxes	214	195
Profit	600	445
Profit attributable to non-controlling interests	-	-
Profit attributable to owners of parent	600	445

Quarterly Consolidated Statement of Comprehensive Income (For the three months)

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Profit	600	445
Other comprehensive income		
Valuation difference on available-for-sale securities	34	(10)
Foreign currency translation adjustment	(18)	0
Remeasurements of defined benefit plans, net of tax	(12)	(16)
Total other comprehensive income	4	(26)
Comprehensive income	605	419
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	605	419
Comprehensive income attributable to non-controlling interests	-	-

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on going concern assumption)

Not applicable.

(Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements)

(Tax expense calculation)

Tax expenses on profit before income taxes are calculated by multiplying profit before income taxes by the reasonably estimated effective tax rate for the consolidated fiscal year including the first quarter of the consolidated accounting period under review after applying tax effect accounting.

(Notes in case of significant changes in shareholders' equity)

Not applicable.

(Notes on Cash Flow Statement)

Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year are not prepared.

Depreciation (Including depreciation of intangible assets.) for the first quarter of the current fiscal year is as follows.

(Millions of yen)

	Previous consolidated fiscal year (From April 1, 2025 to June 30, 2025)	Current consolidated fiscal year (From April 1, 2026 to June 30, 2026)
Depreciation	548	606

(Segment information)

I Previous consolidated fiscal year (From April 1, 2025 to June 30, 2025)

The Group is a single segment of the reagents business, so it is omitted.

II Current consolidated fiscal year (From April 1, 2026 to June 30, 2026)

The Group is a single segment of the reagents business, so it is omitted.